Controlled, prospective trial of steroid treatment in IgA nephropathy

A limitation of low-dose prednisolone therapy

Ritsuko Katafuchi, Kiyoshi Ikeda, Tohru Mizumasa, Hiroshi Tanaka, Takashi Ando, Tetsuro Yanase, Kosuke Masutani, Michiaki Kubo, Satoru Fujimi

Research output: Contribution to journalArticle

97 Citations (Scopus)

Abstract

Background: No accepted therapy has been established for progressive immunoglobulin A (IgA) nephropathy. Methods: A prospective, randomized, controlled trial of low-dose prednisolone therapy was performed in patients with IgA nephropathy with moderate histological characteristics. Forty-three patients in the steroid group and 47 patients in the control group were included in the study. The initial dose of prednisolone was 20 mg/d, gradually tapered to 5 mg/d during 2 years. Results: Baseline urine protein-creatinine ratio (UP-UCR) was significantly greater in the steroid group than in controls. Follow-up duration was 65 ± 25 months in the steroid group and 64 ± 23 months in controls. Changes in UP-UCR from baseline, ie, UP-UCR at last follow-up minus UP-UCR at baseline, were significantly lower in the steroid group than in controls (steroid group, -0.84 ± 1.78; controls, 0.26 ± 1.65; P = 0.0034). Kidney survival was similar in both groups. Patients were divided into two subgroups according to clinical course. There were 28 improved patients and 15 unimproved patients in the steroid group and 27 improved patients and 20 unimproved patients in the control group. In the steroid group, UP-UCR was significantly greater in the unimproved than improved subgroup (3.1 ± 2.6 versus 1.8 ± 1.5). Conclusion: These data suggest that our protocol had an antiproteinuric effect, but could not improve kidney survival. Because the effect of steroid therapy to prevent the progression of IgA nephropathy is believed to be linked closely to reduction in urinary potein, an insufficient dose of prednisolone in our protocol may be the reason for the discrepancy between the effect on proteinuria and kidney survival.

Original languageEnglish
Pages (from-to)972-983
Number of pages12
JournalAmerican Journal of Kidney Diseases
Volume41
Issue number5
DOIs
Publication statusPublished - May 1 2003

Fingerprint

IGA Glomerulonephritis
Prednisolone
Steroids
Control Groups
Therapeutics
Kidney
Proteinuria
Creatinine
Randomized Controlled Trials
Urine

All Science Journal Classification (ASJC) codes

  • Nephrology

Cite this

Controlled, prospective trial of steroid treatment in IgA nephropathy : A limitation of low-dose prednisolone therapy. / Katafuchi, Ritsuko; Ikeda, Kiyoshi; Mizumasa, Tohru; Tanaka, Hiroshi; Ando, Takashi; Yanase, Tetsuro; Masutani, Kosuke; Kubo, Michiaki; Fujimi, Satoru.

In: American Journal of Kidney Diseases, Vol. 41, No. 5, 01.05.2003, p. 972-983.

Research output: Contribution to journalArticle

Katafuchi, R, Ikeda, K, Mizumasa, T, Tanaka, H, Ando, T, Yanase, T, Masutani, K, Kubo, M & Fujimi, S 2003, 'Controlled, prospective trial of steroid treatment in IgA nephropathy: A limitation of low-dose prednisolone therapy', American Journal of Kidney Diseases, vol. 41, no. 5, pp. 972-983. https://doi.org/10.1016/S0272-6386(03)00194-X
Katafuchi, Ritsuko ; Ikeda, Kiyoshi ; Mizumasa, Tohru ; Tanaka, Hiroshi ; Ando, Takashi ; Yanase, Tetsuro ; Masutani, Kosuke ; Kubo, Michiaki ; Fujimi, Satoru. / Controlled, prospective trial of steroid treatment in IgA nephropathy : A limitation of low-dose prednisolone therapy. In: American Journal of Kidney Diseases. 2003 ; Vol. 41, No. 5. pp. 972-983.
@article{cd7b40db4f3b4d22b89f0008df7423bf,
title = "Controlled, prospective trial of steroid treatment in IgA nephropathy: A limitation of low-dose prednisolone therapy",
abstract = "Background: No accepted therapy has been established for progressive immunoglobulin A (IgA) nephropathy. Methods: A prospective, randomized, controlled trial of low-dose prednisolone therapy was performed in patients with IgA nephropathy with moderate histological characteristics. Forty-three patients in the steroid group and 47 patients in the control group were included in the study. The initial dose of prednisolone was 20 mg/d, gradually tapered to 5 mg/d during 2 years. Results: Baseline urine protein-creatinine ratio (UP-UCR) was significantly greater in the steroid group than in controls. Follow-up duration was 65 ± 25 months in the steroid group and 64 ± 23 months in controls. Changes in UP-UCR from baseline, ie, UP-UCR at last follow-up minus UP-UCR at baseline, were significantly lower in the steroid group than in controls (steroid group, -0.84 ± 1.78; controls, 0.26 ± 1.65; P = 0.0034). Kidney survival was similar in both groups. Patients were divided into two subgroups according to clinical course. There were 28 improved patients and 15 unimproved patients in the steroid group and 27 improved patients and 20 unimproved patients in the control group. In the steroid group, UP-UCR was significantly greater in the unimproved than improved subgroup (3.1 ± 2.6 versus 1.8 ± 1.5). Conclusion: These data suggest that our protocol had an antiproteinuric effect, but could not improve kidney survival. Because the effect of steroid therapy to prevent the progression of IgA nephropathy is believed to be linked closely to reduction in urinary potein, an insufficient dose of prednisolone in our protocol may be the reason for the discrepancy between the effect on proteinuria and kidney survival.",
author = "Ritsuko Katafuchi and Kiyoshi Ikeda and Tohru Mizumasa and Hiroshi Tanaka and Takashi Ando and Tetsuro Yanase and Kosuke Masutani and Michiaki Kubo and Satoru Fujimi",
year = "2003",
month = "5",
day = "1",
doi = "10.1016/S0272-6386(03)00194-X",
language = "English",
volume = "41",
pages = "972--983",
journal = "American Journal of Kidney Diseases",
issn = "0272-6386",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - Controlled, prospective trial of steroid treatment in IgA nephropathy

T2 - A limitation of low-dose prednisolone therapy

AU - Katafuchi, Ritsuko

AU - Ikeda, Kiyoshi

AU - Mizumasa, Tohru

AU - Tanaka, Hiroshi

AU - Ando, Takashi

AU - Yanase, Tetsuro

AU - Masutani, Kosuke

AU - Kubo, Michiaki

AU - Fujimi, Satoru

PY - 2003/5/1

Y1 - 2003/5/1

N2 - Background: No accepted therapy has been established for progressive immunoglobulin A (IgA) nephropathy. Methods: A prospective, randomized, controlled trial of low-dose prednisolone therapy was performed in patients with IgA nephropathy with moderate histological characteristics. Forty-three patients in the steroid group and 47 patients in the control group were included in the study. The initial dose of prednisolone was 20 mg/d, gradually tapered to 5 mg/d during 2 years. Results: Baseline urine protein-creatinine ratio (UP-UCR) was significantly greater in the steroid group than in controls. Follow-up duration was 65 ± 25 months in the steroid group and 64 ± 23 months in controls. Changes in UP-UCR from baseline, ie, UP-UCR at last follow-up minus UP-UCR at baseline, were significantly lower in the steroid group than in controls (steroid group, -0.84 ± 1.78; controls, 0.26 ± 1.65; P = 0.0034). Kidney survival was similar in both groups. Patients were divided into two subgroups according to clinical course. There were 28 improved patients and 15 unimproved patients in the steroid group and 27 improved patients and 20 unimproved patients in the control group. In the steroid group, UP-UCR was significantly greater in the unimproved than improved subgroup (3.1 ± 2.6 versus 1.8 ± 1.5). Conclusion: These data suggest that our protocol had an antiproteinuric effect, but could not improve kidney survival. Because the effect of steroid therapy to prevent the progression of IgA nephropathy is believed to be linked closely to reduction in urinary potein, an insufficient dose of prednisolone in our protocol may be the reason for the discrepancy between the effect on proteinuria and kidney survival.

AB - Background: No accepted therapy has been established for progressive immunoglobulin A (IgA) nephropathy. Methods: A prospective, randomized, controlled trial of low-dose prednisolone therapy was performed in patients with IgA nephropathy with moderate histological characteristics. Forty-three patients in the steroid group and 47 patients in the control group were included in the study. The initial dose of prednisolone was 20 mg/d, gradually tapered to 5 mg/d during 2 years. Results: Baseline urine protein-creatinine ratio (UP-UCR) was significantly greater in the steroid group than in controls. Follow-up duration was 65 ± 25 months in the steroid group and 64 ± 23 months in controls. Changes in UP-UCR from baseline, ie, UP-UCR at last follow-up minus UP-UCR at baseline, were significantly lower in the steroid group than in controls (steroid group, -0.84 ± 1.78; controls, 0.26 ± 1.65; P = 0.0034). Kidney survival was similar in both groups. Patients were divided into two subgroups according to clinical course. There were 28 improved patients and 15 unimproved patients in the steroid group and 27 improved patients and 20 unimproved patients in the control group. In the steroid group, UP-UCR was significantly greater in the unimproved than improved subgroup (3.1 ± 2.6 versus 1.8 ± 1.5). Conclusion: These data suggest that our protocol had an antiproteinuric effect, but could not improve kidney survival. Because the effect of steroid therapy to prevent the progression of IgA nephropathy is believed to be linked closely to reduction in urinary potein, an insufficient dose of prednisolone in our protocol may be the reason for the discrepancy between the effect on proteinuria and kidney survival.

UR - http://www.scopus.com/inward/record.url?scp=0038079335&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038079335&partnerID=8YFLogxK

U2 - 10.1016/S0272-6386(03)00194-X

DO - 10.1016/S0272-6386(03)00194-X

M3 - Article

VL - 41

SP - 972

EP - 983

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

SN - 0272-6386

IS - 5

ER -